Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Fungal infections following chimeric antigen receptor T-cell (CAR-T) cell therapy: A retrospective case-control study in the south-central US

View Full Paper
Ask AI
Bookmark
Share

Authors

MBMaryam BibiATAminah TayyabNPNiveditha Popuri

Discussion

Loading...

Member takes

Overview

Retrospective case-control study shows invasive fungal infection risk in CAR-T patients, highlighting immunosuppression and neutropenia effects.

Key Points

  • Invasive fungal infections significantly increase mortality risk following CAR-T therapy, particularly in patients with B-ALL.
  • Among 94 patients treated, 7.4% suffered from an invasive fungal infection within one year, despite receiving prophylaxis.
  • Analysis involved a retrospective case-control study assessing clinical outcomes related to CAR-T therapy and related infections.
  • Findings suggest targeted antifungal prophylactic strategies are urgently needed for high-risk CAR-T recipients.

Cite This Study

Bibi et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da4ehttps://doi.org/10.1182/blood-2025-2781
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prevalence and mortality of infections following CAR T-cell therapy in children, adolescents, and young adults: A systematic review and meta-analysis2025
  2. 2Severe infections after CD19-directed chimeric antigen receptor T-cell therapy for Relapsed/Refractory large B-cell lymphoma, a retrospective real-life study from the DESCAR-T registry (LYSA)2025
  3. 3Infectious Complications Following CD30 Chimeric Antigen Receptor T-cell Therapy in Adults.2025 · 1 citations
  4. 4Infectious complications after CAR T-cell therapy: mechanisms, risk stratification, and prevention2026 · 1 citations
  5. 5Late‐Onset Invasive Aspergillosis With Pituitary Involvement and Dysfunction Following CD19 Chimeric Antigen Receptor T‐Cell Therapy2025 · 1 citations